Available in once-weekly pen device in five strengths
Emcure Pharmaceuticalsannounced the commercial launch of Poviztra, semaglutide injection, across India. With this launch Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management. These are available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg.
Semaglutide injection (Poviztra) is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes and has demonstrated robust real-world use. Globally, the molecule has nearly a decade of market presence, 38 million patient-years* of exposure, and a strong safety and efficacy profile backed by comprehensive data.1-4
Poviztra is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Poviztra is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. In clinical trials, the semaglutide formulation achieved weight loss of more than 20% in many patients.
Satish Mehta, CEO and MD, Emcure Pharmaceuticals, said, “India is facing a significant obesity crisis, having nearly 254 million people living with generalised obesity and an additional 351 million living with abdominal obesity.5 The introduction of Poviztra® marks an important step in expanding equitable access to scientifically validated weight-management solutions. Through our strong distribution capabilities and pan-India reach, we aim to ensure that more patients can benefit from advanced therapies like semaglutide.”
